Table 1.
HLA-B*5701 and clinically diagnosed abacavir hypersensitivity reaction.
| Article | Population | Description | Sensitivity | Specificity | PPV | NPV | Incidence | NNG | Frequency carriers in population (%) |
|---|---|---|---|---|---|---|---|---|---|
| Berka et al. (2012) | Canada | Prospective cohort study. N = 489 | 0.90 | 1 | 1 | 0.996 | 0.037 i | 27 | 4.1 (Berka et al., 2012) |
| Hetherington et al. (2002) | North America | Case-control study. 85 cases + 115 controls | 0.554 | 0.988 | 0.666 | 0.980 | 0.043iii (Hetherington et al., 2001) | 42 | 7.2 (USA NMDP European Caucasian) (McCabe et al., 2020) |
| Hughes et al. (2004) | UK | Case-control study. 13 cases + 51 controls | 0.462 | 0.902 | 0.153 | 0.978 | 0.037iii (Symonds et al., 2002) | 59 | 9.0 (England Blood Donors of Mixed Ethnicity) (McCabe et al., 2020) |
| Mallal et al. (2002) | West Australia | Cohort study. N = 200. 18 cases. | 0.778 | 0.976 | 0.778 | 0.976 | 0.090 i | 14 | 8.7 (Mallal et al., 2002) |
| Martin et al. (2004) | West Australia | Cohort study. N = 248. Includes Mallal et al. (2002) patients. Mallal’s cases were reassessed using updated diagnostic criteria | 0.947 | 0.983 | 0.818 | 0.996 | 0.073i | 14 | 8.5 (Martin et al., 2004) |
| Mallal et al. (2008) | 19 countries. Mostly white. | Randomized clinical trial. 980 prospectively genotyped + 976 control group retrospectively genotyped | 0.455 | 0.976 | 0.612 | 0.955 | 0.078 i | 29 | 5.6 (Mallal et al., 2008) |
| Rauch et al. (2008) | Switzerland | prospective cohort study. N= 1,877 of which 149 suspected cases (of which 27 likely). 140 controls. Clinically suspected | 0.309 | 0.986 | 0.244 | 0.990 | 0.0794i | 41 | 6.0 (Rauch et al., 2008) |
| Clinically likely | 0.778 | 0.986 | 0.827 | 0.981 | 0.0144i | 89 | |||
| Rodriguez et al. (2007) | Spain | case-control study. 26 cases + 27 controls. | 0.423 | 0.963 | 0.491 | 0.952 | 0.078iii (Mallal et al., 2008) | 30 | 4.7 (Spain (Catalunya, Navarra, Extremadura, Aaragón, Cantabria),(McCabe et al., 2020) |
| Saag et al. (2008) | US White | case-control study. 130 white cases + 202 controls | 0.442 | 0.960 | 0.492 | 0.952 | 0.080iii (Brothers C et al., 2006) | 28 | 7.2 (USA NMDP European Caucasian) (McCabe et al., 2020) |
| Saag et al. (2008) | US Black | case-control study. 69 black cases + 206 controls | 0.145 | 0.990 | 0.358 | 0.969 | 0.036iii (Brothers C et al., 2006) | 192 | 1.4 (USA NMDP African American pop 2) (McCabe et al., 2020) |